A 5-Year Update on the Clinical Development of Cancer Cell-Based Vaccines for Glioblastoma Multiforme
Glioblastoma multiforme (GBM) is considered one of the most aggressive forms of brain cancer with a 15-month median survival, despite advancements in surgery, radiotherapy, and chemotherapy. The immune-suppressed tumor microenvironment and the blood–brain barrier are major contributors to its poor p...
Saved in:
| Main Authors: | Almohanad A. Alkayyal, Ahmad Bakur Mahmoud |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/3/376 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Autologous Dendritic Cell Vaccine Optimization for Therapy of Patients with Disseminated Malignant Ne
by: T. L. Nehaeva
Published: (2016-02-01) -
The Role of Insulin Receptor Substrate 4 (IRS4) Protein in the Radiotherapy Response of Glioblastoma Multiforme (GBM) Cells
by: Gökhan Görgişen, et al.
Published: (2024-10-01) -
An oncolytic herpes simplex virus armed with IL-12 for treatment of preclinical glioblastoma
by: Joseph W. Jackson, et al.
Published: (2025-09-01) -
IMMUNOTHERAPY FOR MELANOMA
by: E. A. Borobova, et al.
Published: (2017-09-01) -
Theory and Practice of Immunotherapy Directed against the PRAME Antigen
by: VA Misyurin
Published: (2018-04-01)